All posts by: Michael Zand

About Michael Zand

Two-part system turns stem cells into whatever you want – Penn State News

Continue reading

2017-06-05 NEWS

Penn State News

Two-part system turns stem cells into whatever you want
Penn State News
UNIVERSITY PARK, Pa. — Whether using embryonic or adult stem cells, coercing these master cells to convert to the desired target cell and reproduce flawlessly is difficult. Now an international team of researchers has a two-part system that can

and more »

Continue reading

2017-06-05 NEWS

STAT

A first: All respond to CART therapy in a blood cancer study
STAT
HICAGO — Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that’s on the rise. Although it’s early and the study is small — 35 people — every patient responded and all but two were in
CAR T- Cell Therapy Could Be A Promising Treatment For Multiple Myeloma CancerScience World Report
Therapy Shows High Remission Rates in Multiple MyelomaCuretoday.com
Gene-Based Therapy That Reprograms Immune Cells Offers Hope For Multiple Myeloma CureTech Times
WBOC TV 16
all 18 news articles »
Continue reading

2017-06-05 NEWS

Science Daily

CRISPR tech leads to new screening tool for Parkinson’s disease
Science Daily
They are using CRISPR Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology. The system is one of research’s fastest growing biomedical techniques that allows scientists to make specific changes in the DNA of plants …

and more »

Continue reading

2017-06-05 NEWS

FierceBiotech

CAR T-Cell therapy sends multiple myeloma into lasting remission
Science Daily
CAR T-cell therapy is custom-made for each patient. The patient’s own T cells are collected, genetically reprogrammed in a lab, and injected back into the patient. The reprogramming involves inserting an artificially designed gene into the T-cell
CAR T-cell therapy shows promise for patients with myelomaHealio
ASCO dark horse Nanjing Legend Biotech shines with promising CART dataFierceBiotech
Bluebird is pretty chirpy about its anti-BCMA CART therapy resultsMedCity News
TheStreet.com –Reuters –Business Wire (press release)
all 14 news articles »